Belumosudil in Minority Populations with cGVHD

Phase 2, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Primary endpoints: Number of participants with treatment emergent adverse events and serious adverse events at 48 months, Number of participants with clinically significant laboratory abnormalities at 12 months and 4 more. Planned start Jun 2025; status: withdrawn.